Table 6.
ADME analysis of synthesized (E)-2-(3-(substitutedstyryl)-5-(substitutedphenyl)-4,5-dihydropyrazol-1-yl)benzo[d]thiazole derivatives by Pre ADMET online server
| Comp | Human intestinal absorption (HIA, %) | In vitro Caco-2 cell permeability (nm/s) | In vitro MDCK cell permeability (nm/s) | In vitro plasma protein binding (%) | In vivo blood brain barrier penetration (C.brain/C. blood) | Pgp_inhibition |
|---|---|---|---|---|---|---|
| Z1 | 98.23 | 57.80 | 0.177 | 100 | 0.41 | Inhibitor |
| Z2 | 98.23 | 57.03 | 28.85 | 97.62 | 0.82 | Inhibitor |
| Z3 | 98.48 | 01.82 | 0.04 | 93.74 | 0.32 | Inhibitor |
| Z4 | 98.48 | 01.08 | 0.04 | 94.60 | 0.52 | Inhibitor |
| Z5 | 98.48 | 01.01 | 0.04 | 93.74 | 0.57 | Inhibitor |
| Z6 | 98.23 | 56.83 | 12.79 | 97.67 | 0.51 | Inhibitor |
| Z7 | 96.02 | 29.91 | 0.19 | 95.10 | 0.59 | Inhibitor |
| Z8 | 96.02 | 39.58 | 0.04 | 95.28 | 0.44 | Inhibitor |
| Z9 | 98.27 | 56.27 | 0.02 | 100 | 0.41 | Inhibitor |
| Z10 | 97.95 | 38.08 | 0.37 | 93.08 | 0.80 | Inhibitor |
| Z11 | 97.68 | 44.87 | 0.04 | 91.56 | 1.97 | Inhibitor |
| Z12 | 97.86 | 37.63 | 63.42 | 94.17 | 2.18 | Inhibitor |
| Z13 | 97.87 | 53.83 | 0.05 | 96.94 | 0.46 | Inhibitor |
| Z14 | 97.68 | 34.80 | 1.32 | 91.32 | 3.62 | Inhibitor |
| Z15 | 97.68 | 36.02 | 0.05 | 91.64 | 2.02 | Inhibitor |
| Z16 | 98.35 | 56.16 | 0.02 | 100 | 0.74 | Inhibitor |
| Z17 | 98.37 | 56.16 | 0.05 | 100 | 0.60 | Inhibitor |
| Z18 | 98.37 | 56.64 | 0.07 | 100 | 0.60 | Inhibitor |
| Z19 | 97.69 | 33.42 | 0.04 | 90.39 | 2.81 | Inhibitor |
| Z20 | 98.27 | 36.86 | 0.04 | 90.12 | 2.41 | Inhibitor |
Caco-2- Cells derived from human colon adenocarcinomas; MDCK- Medin-Darbey Canine Kidney Epithelial Cells; Pgp- P- glycoprotein (plasma membrane protein)